FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake
(Reuters) – The U.S. Food and Drug Administration on Friday approved Johnson & Johnson’s treatment for patients with a form of bladder cancer.
The green signal to the drug, Balversa, makes it the first approved treatment for bladder cancer that targets a genetic alteration known as FGFR3 or FGFR2, the FDA said.
Patients can take the drug using an FDA-approved companion diagnostic device.
The approval was based on a clinical trial in 87 patients whose cancer had progressed after chemotherapy.
The trial showed that about 32 percent of patients responded to J&J’s treatment.
Shares of Incyte Corp, which is also developing a cancer treatment with the same mechanism of action that targets mutations in the FGFR molecules, were down 2 percent at $79.45.
J&J shares were flat at $135.45 in afternoon trading.
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and James Emmanuel
Powered by WPeMatico